K M Schwetz - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

K M Schwetz

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

Archives of Neurology|June 1, 1986

Multiple sclerosis. The problem of incorrect diagnosisR A Rudick, R B Schiffer, K M Schwetz, et al.

Applied Nursing Research : ANR|May 1, 1996

Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trialN M Wineman, K M Schwetz, D E Goodkin, et al.

Annals of Neurology|January 1, 1995

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.

The Online Journal of Current Clinical Trials|September 25, 1992

Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicityD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.

Pageof 1

Search research articles

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

Archives of Neurology|June 1, 1986

Multiple sclerosis. The problem of incorrect diagnosisR A Rudick, R B Schiffer, K M Schwetz, et al.

Applied Nursing Research : ANR|May 1, 1996

Relationships among illness uncertainty, stress, coping, and emotional well-being at entry into a clinical drug trialN M Wineman, K M Schwetz, D E Goodkin, et al.

Annals of Neurology|January 1, 1995

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosisD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.

The Online Journal of Current Clinical Trials|September 25, 1992

Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicityD E Goodkin, R A Rudick, S VanderBrug Medendorp, et al.

Pageof 1